Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (1->4)-beta-D-glucan | multiple interactions | ISO | Cab39l (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of CAB39L mRNA | CTD | PMID:36331819 | 17alpha-ethynylestradiol | increases expression | ISO | Cab39l (Mus musculus) | 6480464 | Ethinyl Estradiol results in increased expression of CAB39L mRNA | CTD | PMID:17942748 | 17alpha-ethynylestradiol | multiple interactions | ISO | Cab39l (Mus musculus) | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of CAB39L mRNA | CTD | PMID:17942748 | 17beta-estradiol | multiple interactions | ISO | CAB39L (Homo sapiens) | 6480464 | EGF protein promotes the reaction [Estradiol results in decreased expression of CAB39L mRNA] | CTD | PMID:24758408 | 17beta-estradiol | decreases expression | ISO | CAB39L (Homo sapiens) | 6480464 | Estradiol results in decreased expression of CAB39L mRNA | CTD | PMID:21185374 more ... | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | Cab39l (Mus musculus) | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of CAB39L mRNA | CTD | PMID:17942748 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of CAB39L mRNA | CTD | PMID:33387578 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Cab39l (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of CAB39L mRNA | CTD | PMID:21570461 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Cab39l (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of CAB39L mRNA | CTD | PMID:19770486 and PMID:33956508 | 2,4,6-trinitrotoluene | affects expression | EXP | | 6480464 | Trinitrotoluene affects the expression of CAB39L mRNA | CTD | PMID:21346803 | acrylamide | increases expression | ISO | CAB39L (Homo sapiens) | 6480464 | Acrylamide results in increased expression of CAB39L mRNA | CTD | PMID:32763439 | aflatoxin B1 | decreases expression | ISO | Cab39l (Mus musculus) | 6480464 | Aflatoxin B1 results in decreased expression of CAB39L mRNA | CTD | PMID:19770486 | antirheumatic drug | increases expression | ISO | CAB39L (Homo sapiens) | 6480464 | Antirheumatic Agents results in increased expression of CAB39L mRNA | CTD | PMID:24449571 | arsenite(3-) | multiple interactions | ISO | CAB39L (Homo sapiens) | 6480464 | arsenite inhibits the reaction [G3BP1 protein binds to CAB39L mRNA] | CTD | PMID:32406909 | arsenous acid | decreases expression | ISO | CAB39L (Homo sapiens) | 6480464 | Arsenic Trioxide results in decreased expression of CAB39L protein alternative form | CTD | PMID:29059232 | arsenous acid | decreases response to substance | ISO | CAB39L (Homo sapiens) | 6480464 | CAB39L protein alternative form results in decreased susceptibility to Arsenic Trioxide | CTD | PMID:29059232 | arsenous acid | multiple interactions | ISO | CAB39L (Homo sapiens) | 6480464 | CAB39L protein alternative form inhibits the reaction [Arsenic Trioxide results in decreased expression of CCNB1 protein] more ... | CTD | PMID:29059232 | arsenous acid | increases expression | ISO | CAB39L (Homo sapiens) | 6480464 | Arsenic Trioxide results in increased expression of CAB39L mRNA | CTD | PMID:27829220 | benzo[a]pyrene | increases expression | ISO | Cab39l (Mus musculus) | 6480464 | Benzo(a)pyrene results in increased expression of CAB39L mRNA | CTD | PMID:27195522 | benzo[a]pyrene | affects methylation | ISO | CAB39L (Homo sapiens) | 6480464 | Benzo(a)pyrene affects the methylation of CAB39L 5' UTR | CTD | PMID:27901495 | benzo[e]pyrene | increases methylation | ISO | CAB39L (Homo sapiens) | 6480464 | benzo(e)pyrene results in increased methylation of CAB39L intron | CTD | PMID:30157460 | beta-naphthoflavone | multiple interactions | EXP | | 6480464 | [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in decreased expression of CAB39L mRNA | CTD | PMID:18164116 | bisphenol A | increases methylation | EXP | | 6480464 | bisphenol A results in increased methylation of CAB39L gene | CTD | PMID:28505145 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of CAB39L mRNA | CTD | PMID:34947998 | butanal | decreases expression | ISO | CAB39L (Homo sapiens) | 6480464 | butyraldehyde results in decreased expression of CAB39L mRNA | CTD | PMID:26079696 | cadmium atom | increases expression | ISO | CAB39L (Homo sapiens) | 6480464 | Cadmium results in increased expression of CAB39L mRNA | CTD | PMID:23369406 | cadmium dichloride | increases expression | ISO | CAB39L (Homo sapiens) | 6480464 | Cadmium Chloride results in increased expression of CAB39L mRNA | CTD | PMID:26314618 | calcitriol | decreases expression | ISO | CAB39L (Homo sapiens) | 6480464 | Calcitriol results in decreased expression of CAB39L mRNA | CTD | PMID:21592394 | calcitriol | multiple interactions | ISO | CAB39L (Homo sapiens) | 6480464 | [Testosterone co-treated with Calcitriol] results in decreased expression of CAB39L mRNA | CTD | PMID:21592394 | carbon nanotube | decreases expression | ISO | Cab39l (Mus musculus) | 6480464 | Nanotubes more ... | CTD | PMID:25554681 and PMID:25620056 | chlorpyrifos | decreases expression | ISO | Cab39l (Mus musculus) | 6480464 | Chlorpyrifos results in decreased expression of CAB39L mRNA | CTD | PMID:37019170 | cisplatin | multiple interactions | ISO | CAB39L (Homo sapiens) | 6480464 | [Cisplatin co-treated with jinfukang] results in decreased expression of CAB39L mRNA | CTD | PMID:27392435 | cisplatin | decreases expression | ISO | CAB39L (Homo sapiens) | 6480464 | Cisplatin results in decreased expression of CAB39L mRNA | CTD | PMID:27392435 | cocaine | multiple interactions | ISO | Cab39l (Mus musculus) | 6480464 | [Cocaine co-treated with FOS protein mutant form] results in increased expression of CAB39L mRNA | CTD | PMID:18355967 | crocidolite asbestos | decreases expression | ISO | Cab39l (Mus musculus) | 6480464 | Asbestos and Crocidolite results in decreased expression of CAB39L mRNA | CTD | PMID:29279043 | cyclosporin A | decreases expression | ISO | Cab39l (Mus musculus) | 6480464 | Cyclosporine results in decreased expression of CAB39L mRNA | CTD | PMID:19770486 | cytarabine | decreases expression | ISO | CAB39L (Homo sapiens) | 6480464 | Cytarabine results in decreased expression of CAB39L mRNA | CTD | PMID:21198554 | diarsenic trioxide | decreases response to substance | ISO | CAB39L (Homo sapiens) | 6480464 | CAB39L protein alternative form results in decreased susceptibility to Arsenic Trioxide | CTD | PMID:29059232 | diarsenic trioxide | decreases expression | ISO | CAB39L (Homo sapiens) | 6480464 | Arsenic Trioxide results in decreased expression of CAB39L protein alternative form | CTD | PMID:29059232 | diarsenic trioxide | multiple interactions | ISO | CAB39L (Homo sapiens) | 6480464 | CAB39L protein alternative form inhibits the reaction [Arsenic Trioxide results in decreased expression of CCNB1 protein] more ... | CTD | PMID:29059232 | diarsenic trioxide | increases expression | ISO | CAB39L (Homo sapiens) | 6480464 | Arsenic Trioxide results in increased expression of CAB39L mRNA | CTD | PMID:27829220 | dicrotophos | decreases expression | ISO | CAB39L (Homo sapiens) | 6480464 | dicrotophos results in decreased expression of CAB39L mRNA | CTD | PMID:28302478 | diethylstilbestrol | increases expression | EXP | | 6480464 | Diethylstilbestrol results in increased expression of CAB39L mRNA | CTD | PMID:36653537 | dorsomorphin | multiple interactions | ISO | CAB39L (Homo sapiens) | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | ethanol | affects expression | ISO | Cab39l (Mus musculus) | 6480464 | Ethanol affects the expression of CAB39L mRNA | CTD | PMID:30319688 | ethylparaben | increases expression | ISO | CAB39L (Homo sapiens) | 6480464 | ethyl-p-hydroxybenzoate results in increased expression of CAB39L mRNA | CTD | PMID:37690743 | finasteride | increases expression | EXP | | 6480464 | Finasteride results in increased expression of CAB39L mRNA | CTD | PMID:24136188 | glycine betaine | decreases expression | EXP | | 6480464 | Betaine results in decreased expression of CAB39L mRNA | CTD | PMID:26391144 | kojic acid | increases expression | ISO | CAB39L (Homo sapiens) | 6480464 | kojic acid results in increased expression of CAB39L mRNA | CTD | PMID:16595896 | mercury dibromide | increases expression | ISO | CAB39L (Homo sapiens) | 6480464 | mercuric bromide results in increased expression of CAB39L mRNA | CTD | PMID:26272509 | mercury dibromide | multiple interactions | ISO | CAB39L (Homo sapiens) | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAB39L mRNA | CTD | PMID:27188386 | methamphetamine | decreases expression | ISO | Cab39l (Mus musculus) | 6480464 | Methamphetamine results in decreased expression of CAB39L mRNA | CTD | PMID:26307267 | methapyrilene | increases methylation | ISO | CAB39L (Homo sapiens) | 6480464 | Methapyrilene results in increased methylation of CAB39L intron | CTD | PMID:30157460 | methylmercury chloride | increases expression | ISO | CAB39L (Homo sapiens) | 6480464 | methylmercuric chloride results in increased expression of CAB39L mRNA | CTD | PMID:28001369 | N,N-diethyl-m-toluamide | multiple interactions | EXP | | 6480464 | [Permethrin co-treated with DEET] results in increased methylation of CAB39L gene | CTD | PMID:33148267 | N-nitrosodiethylamine | multiple interactions | EXP | | 6480464 | [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in decreased expression of CAB39L mRNA | CTD | PMID:18164116 | nickel atom | decreases expression | ISO | CAB39L (Homo sapiens) | 6480464 | Nickel results in decreased expression of CAB39L mRNA | CTD | PMID:24768652 and PMID:25583101 | oxaliplatin | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of CAB39L mRNA | CTD | PMID:25729387 | paracetamol | affects expression | ISO | Cab39l (Mus musculus) | 6480464 | Acetaminophen affects the expression of CAB39L mRNA | CTD | PMID:17562736 | pentachlorophenol | increases expression | ISO | Cab39l (Mus musculus) | 6480464 | Pentachlorophenol results in increased expression of CAB39L mRNA | CTD | PMID:23892564 | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | Cab39l (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of CAB39L mRNA | CTD | PMID:36331819 | permethrin | multiple interactions | EXP | | 6480464 | [Permethrin co-treated with DEET] results in increased methylation of CAB39L gene | CTD | PMID:33148267 | phenethyl isothiocyanate | increases expression | ISO | CAB39L (Homo sapiens) | 6480464 | phenethyl isothiocyanate results in increased expression of CAB39L mRNA | CTD | PMID:26678675 | phenylmercury acetate | increases expression | ISO | CAB39L (Homo sapiens) | 6480464 | Phenylmercuric Acetate results in increased expression of CAB39L mRNA | CTD | PMID:26272509 | phenylmercury acetate | multiple interactions | ISO | CAB39L (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAB39L mRNA | CTD | PMID:27188386 | PhIP | decreases expression | ISO | CAB39L (Homo sapiens) | 6480464 | 2-amino-1-methyl-6-phenylimidazo(4 and 5-b)pyridine results in decreased expression of CAB39L mRNA | CTD | PMID:20816883 | pirinixic acid | multiple interactions | ISO | Cab39l (Mus musculus) | 6480464 | [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of CAB39L mRNA | CTD | PMID:19710929 | rimonabant | multiple interactions | ISO | Cab39l (Mus musculus) | 6480464 | Rimonabant inhibits the reaction [Dietary Fats results in increased expression of CAB39L mRNA] | CTD | PMID:19030233 | SB 431542 | multiple interactions | ISO | CAB39L (Homo sapiens) | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | serpentine asbestos | increases expression | ISO | CAB39L (Homo sapiens) | 6480464 | Asbestos and Serpentine results in increased expression of CAB39L mRNA | CTD | PMID:21148743 | sodium arsenite | increases expression | ISO | CAB39L (Homo sapiens) | 6480464 | sodium arsenite results in increased expression of CAB39L mRNA | CTD | PMID:24516582 | sodium arsenite | decreases expression | ISO | CAB39L (Homo sapiens) | 6480464 | sodium arsenite results in decreased expression of CAB39L mRNA | CTD | PMID:29301061 | sulforaphane | increases expression | ISO | CAB39L (Homo sapiens) | 6480464 | sulforaphane results in increased expression of CAB39L mRNA | CTD | PMID:31838189 | sunitinib | decreases expression | ISO | CAB39L (Homo sapiens) | 6480464 | Sunitinib results in decreased expression of CAB39L mRNA | CTD | PMID:31533062 | testosterone | increases expression | ISO | CAB39L (Homo sapiens) | 6480464 | Testosterone results in increased expression of CAB39L mRNA | CTD | PMID:21592394 | testosterone | multiple interactions | ISO | CAB39L (Homo sapiens) | 6480464 | [Testosterone co-treated with Calcitriol] results in decreased expression of CAB39L mRNA | CTD | PMID:21592394 | topotecan | multiple interactions | EXP | | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of CAB39L mRNA | CTD | PMID:25729387 | toxaphene | decreases expression | EXP | | 6480464 | Toxaphene results in decreased expression of CAB39L mRNA | CTD | PMID:23153324 | trichostatin A | decreases expression | ISO | CAB39L (Homo sapiens) | 6480464 | trichostatin A results in decreased expression of CAB39L mRNA | CTD | PMID:24935251 | triclosan | increases expression | ISO | CAB39L (Homo sapiens) | 6480464 | Triclosan results in increased expression of CAB39L mRNA | CTD | PMID:30510588 | urethane | decreases expression | ISO | CAB39L (Homo sapiens) | 6480464 | Urethane results in decreased expression of CAB39L mRNA | CTD | PMID:28818685 | valproic acid | affects expression | ISO | CAB39L (Homo sapiens) | 6480464 | Valproic Acid affects the expression of CAB39L mRNA | CTD | PMID:25979313 | valproic acid | decreases expression | ISO | CAB39L (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of CAB39L mRNA | CTD | PMID:23179753 and PMID:24935251 | valproic acid | increases expression | ISO | CAB39L (Homo sapiens) | 6480464 | Valproic Acid results in increased expression of CAB39L mRNA | CTD | PMID:26272509 | valproic acid | multiple interactions | ISO | CAB39L (Homo sapiens) | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CAB39L mRNA | CTD | PMID:27188386 | |